MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.890
-0.110 (-5.50%)
At close: Apr 28, 2025, 4:00 PM
1.850
-0.040 (-2.12%)
After-hours: Apr 28, 2025, 7:27 PM EDT
MAIA Biotechnology Employees
MAIA Biotechnology had 13 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,788,820
Market Cap
55.03M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 13 | 0 | - |
Dec 31, 2023 | 13 | -5 | -27.78% |
Dec 31, 2022 | 18 | 9 | 100.00% |
Dec 31, 2021 | 9 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
MAIA News
- 27 days ago - MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders - Business Wire
- 4 weeks ago - MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025 - Business Wire
- 5 weeks ago - MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug - Business Wire
- 5 weeks ago - MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO - Business Wire
- 2 months ago - MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients - Business Wire
- 2 months ago - MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer - Business Wire
- 2 months ago - MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million - Business Wire
- 2 months ago - MAIA Biotechnology Announces Private Placement of $2,715,000 - Business Wire